Join us for the VICB Seminar!

🗓 March 4 | 12:15 PM
📍 1220 MRB III
👤 Robert Coffey
🎙 “Doubling Down On DPEP1”

Don’t miss this exciting research talk!

#VCBSeminar #BiomedicalResearch #DPEP1

Attenuation of natural killer cell cytotoxicity by interaction between NKp30 of NK cells and dipeptidase 1 of colon cancer cells - Scientific Reports Scientific Reports - Attenuation of natural killer cell cytotoxicity by interaction between NKp30 of NK cells and dipeptidase 1 of colon cancer cells

🧬 @springernature.com - nature.com/articles/s41598-025-18475-z finds DPEP1 blocks NK-cell killing in colon cancer.

LSALT peptide is a DPEP1 inhibitor in a Phase II trial targeting CS-AKI. Approval would validate DPEP1 and open oncology exploration.

archbiopartners.com/our-science

#NephSky #DPEP1

Our Publications – Arch Biopartners

📘 2024 BMJ Open study (doi.org/10.1136/bmjopen-2023-076142) co-authored by Arch scientists confirmed LSALT was safe in COVID-19 patients and validated DPEP1 as a therapeutic target—key findings for the CS-AKI trial.
📖 archbiopartners.com/our-science/our-publications/
#LSALTpeptide #DPEP1 #KidneyCare

Redirecting

🧬 Weekly series for new followers—2019 Cell paper (doi.org/10.1016/j.cell.2019.07.017), co-authored by Arch scientists, identified DPEP1 as a driver of neutrophil inflammation in the kidneys, liver, and lungs.
📖 Arch Publications: dub.sh/cell-dpep1-2019
#DPEP1 #ArchScience #LSALTpeptide #KidneyCare

Cilastatin – Arch Biopartners

As part of a new series revisiting key research, Arch is highlighting a 2018 JCI study (doi.org/10.1172/JCI96640) showing how Cilastatin blocks DPEP1-driven contrast uptake and protects kidney function in AKI models.
📖 archbiopartners.com/our-science/cilastatin/
#Cilastatin #DPEP1 #ArchScience

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI) – Arch Biopartn...

🚨 (22 April 2025) Arch Biopartners announced that UHN-TGH (Toronto General Hospital) is prepared to begin recruiting subjects for the Phase II trial of LSALT peptide for CS-AKI.

📖 Full release at – dub.sh/arch-uhn-tgh...

#AKI #CSAKI #KidneyCare #LSALTpeptide #ArchBiopartners #DPEP1 #ArchNews

🧬 2025 JCI Insight study from Vanderbilt used LSALT peptide to reduce neutrophil binding to colorectal cancer (CRC) cells, highlighting DPEP1’s immune role.

Authors suggest LSALT could pair with ICI (immune checkpoint inhibitors) as a potential therapeutic.

#ArchBiopartners #DPEP1 #LSALTpeptide